News & Updates
Filter by Specialty:

GLP-1RAs reduce weight in overweight/obese individuals without diabetes
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) results in significant weight loss in patients with obesity or overweight without diabetes, a study has shown. In addition, the best GLP-1RA agent appears to be semaglutide, showing superior efficacy and low-to-moderate risk of side effects.
GLP-1RAs reduce weight in overweight/obese individuals without diabetes
30 Sep 2023
Lorundrostat may expand treatment toolbox for uncontrolled hypertension
Aldosterone synthase inhibition with lorundrostat confers substantial blood pressure (BP)-lowering benefit in people with uncontrolled hypertension, while having a favourable safety profile, according to data from the phase II Target-HTN trial.
Lorundrostat may expand treatment toolbox for uncontrolled hypertension
29 Sep 2023
Electrofulguration effective against recurrent UTI in menopausal women
Treatment with electrofulguration for antibiotic-refractory recurrent urinary tract infections (UTI) demonstrates durable clinical cure and improvement over 5 years in menopausal women, reducing the need for long-term antibiotics, a study has shown.
Electrofulguration effective against recurrent UTI in menopausal women
25 Sep 2023
Depression, diabetes duration predict sexual dysfunction in women with T1D
Type 1 diabetes (T1D) is significantly associated with the risk of sexual dysfunction among women, according to the results of a systematic review and meta-analysis.
Depression, diabetes duration predict sexual dysfunction in women with T1D
23 Sep 2023
NSAIDs up VTE risk in women using hormonal contraception
Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) appears to increase the risk of venous thromboembolism (VTE) in women using hormonal contraception, reveals a study.
NSAIDs up VTE risk in women using hormonal contraception
20 Sep 2023
Low-dose spironolactone safe, effective in T2D patients with chronic kidney disease
Treatment with low-dose spironolactone results in reduced albuminuria without causing hyperkalaemia in patients with type 2 diabetes (T2D), reports a study.